中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 1
Jan.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(1): 217-221

Research advances in liver injury associated with thyroid dysfunction

DOI: 10.12449/JCH260128

  • Department of Infection and Hepatology，The First Affiliated Hospital of Kunming Medical University，Kunming 650032，China

Research funding:

National Natural Science Foundation of China (82160801);

Yunnan Province“Ten Thousand Talents Program” Distinguished Physician Project (YNWR-MY-2020-018)

More Information
  • Corresponding author: LI Wu， liwukm@qq.com （ORCID： 0000-0002-1222-3629）
  • Received Date: 2025-06-11
  • Accepted Date: 2025-07-21
  • Published Date: 2026-01-25
    Abstract
  • The thyroid gland is the largest endocrine organ in the human body， and its dysfunction can cause varying degrees of liver injury， leading to liver failure in severe cases. Patients with hyperthyroidism have a relatively high incidence rate of liver dysfunction， manifesting as hepatocellular injury or cholestatic liver injury， while hypothyroidism is closely associated with metabolic dysfunction-associated fatty liver disease. Autoimmune thyroid diseases， including Hashimoto’s thyroiditis and subacute thyroiditis， are commonly comorbid with autoimmune liver disease. In addition， medications such as antithyroid drugs， amiodarone， and immune checkpoint inhibitors can cause severe liver injury through direct toxicity or immune-mediated mechanisms. Although significant progress has been achieved in related diagnosis and treatment techniques in recent years， there are still many challenges in pathogenesis， individualized treatment strategies， early warning， and prognostic evaluation. This article systematically reviews the research advances in liver injury associated with thyroid dysfunction and proposes the directions for future research， in order to provide guidance for clinical diagnosis and treatment.

     

    • FullText(HTML)
  • loading
    • References(45)
  • [1]
    YORKE E. Hyperthyroidism and liver dysfunction: A review of a common comorbidity[J]. Clin Med Insights Endocrinol Diabetes, 2022, 15: 11795514221074672. DOI: 10.1177/11795514221074672.
    [2]
    LIU H, CHEN P, LI F. The impact of hypothyroidism on chronic liver disease.[J]. J Clin Hepatol, 2021, 37( 4): 969- 972. DOI: 10.3969/j.issn.1001-5256.2021.04.054.

    刘欢, 陈鹏, 李菲. 甲状腺功能减退对慢性肝病的影响[J]. 临床肝胆病杂志, 2021, 37( 4): 969- 972. DOI: 10.3969/j.issn.1001-5256.2021.04.054.
    [3]
    MEDHIOUB M, KHSIBA A, MAHMOUDI M, et al. Thyroid storm-induced acute liver dysfunction and portal hypertension in a patient with Graves’ disease: A case report[J]. Future Sci OA, 2024, 10( 1): FSO929. DOI: 10.2144/fsoa-2023-0180.
    [4]
    FAN H, LI LL, LIU ZQ, et al. Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease[J]. BMC Gastroenterol, 2023, 23( 1): 3. DOI: 10.1186/s12876-022-02612-3.
    [5]
    CHAKER L, COOPER DS, WALSH JP, et al. Hyperthyroidism[J]. Lancet, 2024, 403( 10428): 768- 780. DOI: 10.1016/S0140-6736(23)02016-0.
    [6]
    SCAPPATICCIO L, LONGO M, MAIORINO MI, et al. Abnormal liver blood tests in patients with hyperthyroidism: Systematic review and meta-analysis[J]. Thyroid, 2021, 31( 6): 884- 894. DOI: 10.1089/thy.2020.0715.
    [7]
    ZENG BM, YUAN L, CHU J, et al. Challenges in early identification of causes and treatment of cholestasis in patients with hyperthyroidism: A case report and literature review[J]. J Int Med Res, 2020, 48( 3): 300060519891018. DOI: 10.1177/0300060519891018.
    [8]
    MANTOVANI A, CSERMELY A, BILSON J, et al. Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis[J]. Gut, 2024, 73( 9): 1554- 1561. DOI: 10.1136/gutjnl-2024-332491.
    [9]
    XIANG LL, CAO YT, SUN J, et al. Association between thyroid function and nonalcoholic fatty liver disease: A dose-response meta-analysis[J]. Front Endocrinol(Lausanne), 2024, 15: 1399517. DOI: 10.3389/fendo.2024.1399517.
    [10]
    MARAIKAYAR T, LOKESH S, MARAIKAYAR F, et al. Burden of non-alcoholic fatty liver disease in subclinical hypothyroidism[J]. J Clin Sci Res, 2023, 12( 4): 262- 266. DOI: 10.4103/jcsr.jcsr_175_22.
    [11]
    LU YM, XING CH, ZHANG CG, et al. Promotion of IL-17/NF-κB signaling in autoimmune thyroid diseases[J]. Exp Ther Med, 2022, 25( 1): 51. DOI: 10.3892/etm.2022.11750.
    [12]
    KESKİN Ç, GÖKÇAY CANPOLAT A, CANLAR Ş, et al. A detailed analysis of thyroid disorders in autoimmune liver diseases[J]. J Health Sci Med/JHSM/jhsm, 2023, 6( 5): 888- 892. DOI: 10.32322/jhsm.1324609.
    [13]
    FLOREANI A, MANGINI C, REIG A, et al. Thyroid dysfunction in primary biliary cholangitis: A comparative study at two European centers[J]. Am J Gastroenterol, 2017, 112( 1): 114- 119. DOI: 10.1038/ajg.2016.479.
    [14]
    KHOURY T, KADAH A, MARI A, et al. Thyroid dysfunction is prevalent in autoimmune hepatitis: A case control study[J]. Isr Med Assoc J, 2020, 22( 2): 100- 103.
    [15]
    ZORNITZKI T, MILDINER S, SCHILLER T, et al. Subacute thyroiditis-still a diagnostic challenge: Data from an observational study[J]. Int J Environ Res Public Health, 2022, 19( 15): 9388. DOI: 10.3390/ijerph19159388.
    [16]
    SUZUKI N, NOH JY, HIRUMA M, et al. Analysis of antithyroid drug-induced severe liver injury in 18, 558 newly diagnosed patients with Graves’ disease in Japan[J]. Thyroid, 2019, 29( 10): 1390- 1398. DOI: 10.1089/thy.2019.0045.
    [17]
    KHAN AA, ATA F, AZIZ A, et al. Clinical characteristics and outcomes of patients with antithyroid drug-related liver injury[J]. J Endocr Soc, 2023, 8( 1): bvad133. DOI: 10.1210/jendso/bvad133.
    [18]
    HLAIHEL AF, AL-KHAIRALLA MZH. Levothyroxine-induced liver injury followed by complete recovery upon cessation of the drug: A case report[J]. J Med Case Rep, 2019, 13( 1): 311. DOI: 10.1186/s13256-019-2244-z.
    [19]
    ANUGWOM CM, LEVENTHAL TM. Thyroid disease-induced hepatic dysfunction: A clinical puzzle[J]. ACG Case Rep J, 2021, 8( 4): e00555. DOI: 10.14309/crj.0000000000000555.
    [20]
    VIDANAPATHIRANA M, WIJAYARATNE D. Thyroid storm with acute liver failure and disseminated intravascular coagulation- lessons in diagnosis and treatment[J]. Clin Diabetes Endocrinol, 2024, 10( 1): 24. DOI: 10.1186/s40842-024-00182-9.
    [21]
    LIANG H, SONG K. Comprehensive metabolomics and transcriptomics analysis reveals protein and amino acid metabolic characteristics in liver tissue under chronic hypoxia[J]. PLoS One, 2023, 18( 9): e0291798. DOI: 10.1371/journal.pone.0291798.
    [22]
    AKAMIZU T, SATOH T, ISOZAKI O, et al. Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys[J]. Thyroid, 2012, 22( 7): 661- 679. DOI: 10.1089/thy.2011.0334.
    [23]
    KIZIVAT T, MARIC I, MUDRI D, et al. Hypothyroidism and nonalcoholic fatty liver disease: Pathophysiological associations and therapeutic implications[J]. J Clin Transl Hepatol, 2020, 8( 3): 347- 353. DOI: 10.14218/JCTH.2020.00027.
    [24]
    WANG RF, TAN J, ZHANG GZ, et al. Risk factors of hepatic dysfunction in patients with Graves’ hyperthyroidism and the efficacy of 131iodine treatment[J]. Medicine(Baltimore), 2017, 96( 5): e6035. DOI: 10.1097/MD.0000000000006035.
    [25]
    de MARTIN E, MICHOT JM, PAPOUIN B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors[J]. J Hepatol, 2018, 68( 6): 1181- 1190. DOI: 10.1016/j.jhep.2018.01.033.
    [26]
    LI JH, HUSSAIN Z, ZHU JJ, et al. Role of CYP2A6 in methimazole bioactivation and hepatotoxicity[J]. Chem Res Toxicol, 2021, 34( 12): 2534- 2539. DOI: 10.1021/acs.chemrestox.1c00300.
    [27]
    NICULESCU DA, DUSCEAC R, GALOIU SA, et al. Serial changes of liver function tests before and during methimazole treatment in thyrotoxic patients[J]. Endocr Pract, 2016, 22( 8): 974- 979. DOI: 10.4158/EP161222.OR.
    [28]
    FANG DZ, LI SY, ZHOU CG, et al. Comparing the prognostic impact of 131I and/or artificial liver support system on liver function failure combined with hyperthyroidism[J]. Endocr Connect, 2024, 13( 11): e240330. DOI: 10.1530/EC-24-0330.
    [29]
    TANG LJ, ZENG XM, SUN XP. Efficacy and safety of iodine 131 combined with low-dose methimazole in treating patients with recurrent hyperthyroidism[J]. J Clin Exp Med, 2025, 24( 9): 970- 974. DOI: 10.3969/j.issn.1671-4695.2025.09.019.

    唐丽君, 曾晓敏, 孙晓平. 碘131与小剂量甲巯咪唑联合治疗复发型甲状腺功能亢进患者疗效及安全性探究[J]. 临床和实验医学杂志, 2025, 24( 9): 970- 974. DOI: 10.3969/j.issn.1671-4695.2025.09.019.
    [30]
    MITTENDORF EA, MCHENRY CR. Thyroidectomy for selected patients with thyrotoxicosis[J]. Arch Otolaryngol Head Neck Surg, 2001, 127( 1): 61- 65. DOI: 10.1001/archotol.127.1.61.
    [31]
    ZHENG RD, LIU KM, CHEN K, et al. Lithium carbonate in the treatment of Graves’ disease with ATD-induced hepatic injury or leukopenia[J]. Int J Endocrinol, 2015, 2015: 694023. DOI: 10.1155/2015/694023.
    [32]
    SENDA A, ENDO A, TACHIMORI H, et al. Early administration of glucocorticoid for thyroid storm: Analysis of a national administrative database[J]. Crit Care, 2020, 24( 1): 470. DOI: 10.1186/s13054-020-03188-8.
    [33]
    TAN YW, SUN L, ZHANG K, et al. Therapeutic plasma exchange and a double plasma molecular absorption system in the treatment of thyroid storm with severe liver injury: A case report[J]. World J Clin Cases, 2019, 7( 10): 1184- 1190. DOI: 10.12998/wjcc.v7.i10.1184.
    [34]
    RAO MH, WANG YR, REN JL, et al. Effect of 131I with and without artificial liver support system in patients with Graves’ disease and severe liver dysfunction: A retrospective study[J]. Front Endocrinol(Lausanne), 2022, 13: 1034374. DOI: 10.3389/fendo.2022.1034374.
    [35]
    SINGHA PS, GHOSH S, GHOSH D. Levothyroxine and non-alcoholic fatty liver disease: A mini review[J]. Mini Rev Med Chem, 2024, 24( 2): 128- 138. DOI: 10.2174/1389557523666230314113543.
    [36]
    MUCENIC M. Advancements in autoimmune hepatitis management: Perspectives for future guidelines[J]. World J Hepatol, 2024, 16( 2): 135- 139. DOI: 10.4254/wjh.v16.i2.135.
    [37]
    NARAYANA SK, WOODS DR, BOOS CJ. Management of amiodarone-related thyroid problems[J]. Ther Adv Endocrinol Metab, 2011, 2( 3): 115- 126. DOI: 10.1177/2042018811398516.
    [38]
    de WILDE R, SAERENS M, HOORENS A, et al. Treatment of refractory checkpoint-inhibitor-induced hepatitis with tacrolimus: A case and review of the literature[J]. Int J Transl Med, 2023, 3( 3): 274- 285. DOI: 10.3390/ijtm3030019.
    [39]
    WANG L. Analysis of therapeutic effect of traditional Chinese medicine for soothing liver, regulating Qi, resolving phlegm and promoting blood circulation on thyroid nodules[J]. Pract Clin J Integr Tradit Chin West Med, 2018, 18( 1): 18- 19. DOI: 10.13638/j.issn.1671-4040.2018.01.010.

    王琳. 疏肝理气化痰活血中药对甲状腺结节的治疗效果分析[J]. 实用中西医结合临床, 2018, 18( 1): 18- 19. DOI: 10.13638/j.issn.1671-4040.2018.01.010.
    [40]
    WANG JY, XIE Q. Therapeutic effect of Sanjie Xiaoying Formula on thyroid nodules(syndrome of phlegm binding and blood stasis) and its influence on thyroid function[J]. J Changchun Univ Chin Med, 2024, 40( 9): 995- 999. DOI: 10.13463/j.cnki.cczyy.2024.09.012.

    王济玉, 谢勤. 散结消瘿方治疗甲状腺结节(痰结血瘀证)疗效及对甲状腺功能的影响[J]. 长春中医药大学学报, 2024, 40( 9): 995- 999. DOI: 10.13463/j.cnki.cczyy.2024.09.012.
    [41]
    Expert Committee on Clinical Application of Glycyrrhizin Preparation in the Treatment of Liver Diseases. Expert consensus on clinical application of glycyrrhizin preparation in the treatment of liver diseases[J]. J Clin Hepatol, 2016, 32( 5): 844- 852. DOI: 10.3969/j.issn.1001-5256.2016.05.004.

    甘草酸制剂肝病临床应用专家委员会. 甘草酸制剂肝病临床应用专家共识[J]. 临床肝胆病杂志, 2016, 32( 5): 844- 852. DOI: 10.3969/j.issn.1001-5256.2016.05.004.
    [42]
    HAYAT MH, MOAZZAM Z, ZIOGAS IA, et al. Thyroid storm presenting as acute liver failure in a patient with Graves’ disease[J]. Cureus, 2020, 12( 9): e10333. DOI: 10.7759/cureus.10333.
    [43]
    CARRION AF, CZUL F, AROSEMENA LR, et al. Propylthiouracil-induced acute liver failure: Role of liver transplantation[J]. Int J Endocrinol, 2010, 2010: 910636. DOI: 10.1155/2010/910636.
    [44]
    YANG K, KÖCK K, SEDYKH A, et al. An updated review on drug-induced cholestasis: Mechanisms and investigation of physicochemical properties and pharmacokinetic parameters[J]. J Pharm Sci, 2013, 102( 9): 3037- 3057. DOI: 10.1002/jps.23584.
    [45]
    BOBERG KM, CHAPMAN RW, HIRSCHFIELD GM, et al. Overlap syndromes: The International Autoimmune Hepatitis Group(IAIHG) position statement on a controversial issue[J]. J Hepatol, 2011, 54( 2): 374- 385. DOI: 10.1016/j.jhep.2010.09.002.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (86) PDF downloads(36) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return